SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16.
Liu Y, Kong WY, Yu CF, Shao ZL, Lei QC, Deng YF, Cai GX, Zhuang XF, Sun WS, Wu SG, Wang R, Chen X, Chen GX, Huang HB, Liao YN.
Liu Y, et al.
Acta Pharmacol Sin. 2023 Apr;44(4):853-864. doi: 10.1038/s41401-022-01003-4. Epub 2022 Oct 19.
Acta Pharmacol Sin. 2023.
PMID: 36261513
Free PMC article.